Working… Menu

Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00391924
Recruitment Status : Completed
First Posted : October 25, 2006
Last Update Posted : October 25, 2006
University Medical Center Groningen
Dutch Arthritis Association
Information provided by:
UMC Utrecht

Brief Summary:
The purpose of the study is to examine whether dehydroepiandrosterone (DHEA) administration improves fatigue and general well-being in patients with systemic lupus erythematosus or primary Sjögren's syndrome

Condition or disease Intervention/treatment Phase
Lupus Erythematosus, Systemic Sjogren's Syndrome Drug: Dehydroepiandrosterone Phase 2

Detailed Description:
Fatigue and reduced general well-being are frequent complaints in patients with the chronic autoimmune disorder systemic lupus erythematosus (SLE) or primary Sjögren's syndrome (pSS). Uncontrolled studies suggested that the administration of dehydroepiandrosterone (DHEA) may improve such complaints. The aim of our randomized double-blind placebo-controlled study is to examine the effect of daily oral 200 mg DHEA on fatigue, well-being, and functioning in women with SLE or pSS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration
Study Start Date : May 2000
Study Completion Date : January 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Prasterone

Primary Outcome Measures :
  1. General fatigue
  2. Depressive mood
  3. Mental well-being
  4. Physical functioning
  5. (all measures at baseline, after 3, 6, and 12 months of intake of study medication, and 6 months after cessation of medication intake)

Secondary Outcome Measures :
  1. Self-reported pain,
  2. Fibromyalgia tender points
  3. Erythrocyte sedimentation rate
  4. Hemoglobin
  5. Serum Immunoglobulin-G
  6. Self-reported ocular dryness (in pSS only)
  7. Self-reported oral dryness (in pSS only)
  8. Ocular tear production (in pSS only)
  9. SLE disease activity index (in SLE only)
  10. Bone mineral density (in SLE only)
  11. Dose of glucocorticoids (in SLE only)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • pSS with a focus score >= 1 on minor salivary gland biopsy and fulfilling European classification criteria (Ann Rheum Dis 1996;55:116-21)
  • SLE according to ACR classification criteria (Arthritis Rheum 1982;25:1271-7)
  • Willingness to apply effective contraception (premenopausal women)
  • Written informed consent.

Exclusion Criteria:

  • Pregnancy
  • Pregnancy wish
  • Serum creatinine > 150 µmol/L
  • Glucocorticoid use at a daily dose > 10 mg prednisone (or equivalent)
  • Cyclophosphamide treatment in the preceding year
  • Hyper- or hypothyroidism
  • History of malignancy within the previous 5 years with exception of squamous or basal cell carcinoma of the skin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00391924

Layout table for location information
University Medical Center Groningen
Groningen, Netherlands, 9700RB
University Medical Center Utrecht
Utrecht, Netherlands, 3508GA
Sponsors and Collaborators
UMC Utrecht
University Medical Center Groningen
Dutch Arthritis Association
Layout table for investigator information
Study Chair: Ronald HW Derksen, MD,PhD UMC Utrecht

Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00391924     History of Changes
Other Study ID Numbers: NR 98-2-301
First Posted: October 25, 2006    Key Record Dates
Last Update Posted: October 25, 2006
Last Verified: October 2006
Keywords provided by UMC Utrecht:
Quality of life
Lupus Erythematosus, Systemic
Sjogren's Syndrome
Bone mineral density
Additional relevant MeSH terms:
Layout table for MeSH terms
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Pathologic Processes
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs